On September 7, 2026, Lexaria Bioscience Corp. entered into inducement letter agreements with holders of existing common stock purchase warrants to exercise an aggregate of 453,969 warrants at a reduced price of $12.92 per share. The transaction generated approximately $5.9 million in gross proceeds for working capital and general corporate purposes. In consideration, the Company issued new unregistered Series A and Series B warrants to purchase up to 453,969 shares each, both carrying an exercise price of $12.67 per share and immediate exercisability. The closing is expected on September 9, 2026, with H.C. Wainwright & Co. acting as placement agent for a 7% fee plus warrants to purchase 15,889 shares. Lexaria Bioscience Corp. operates in the biotechnology industry, developing drug delivery platforms and formulations.

On August 28, 2026, Lexaria (AU) Pty Ltd received an Australian R&D Tax Incentive Credit of AUD$3,666,611.98 (approximately USD$2.6M) from the Australian Tax Office. This credit relates to research and development costs for the GLP-1-H24-4 clinical study and has been deposited into the subsidiary's bank account to fund further R&D in Australia. Lexaria Bioscience Corp. is a biotechnology company developing pharmaceutical drug products.

Lexaria Bioscience Corp. received a delisting notification from Nasdaq on August 4, 2026, for failing to maintain the $1.00 minimum bid price requirement within its compliance period. The company had completed a reverse stock split effective August 3, 2026, which raised the share price above the threshold. Lexaria has filed a hearing request and paid the associated fee to suspend the delisting pending review. The company expects to regain compliance with Nasdaq rules before any potential hearing date. Lexaria Bioscience Corp. operates in the biotechnology industry, focusing on cannabis-derived therapeutics.